By Colin Kellaher

 

ObsEva SA (OBSV) on Thursday said a phase 3 study of nolasiban missed its primary endpoint, and the biopharmaceutical company said it would end its in-vitro fertilization program for the drug.

ObsEva said its European confirmatory study of nolasiban in women undergoing embryo transfer following in-vitro fertilization didn't meet the primary endpoint of an increase in ongoing pregnancy rate at 10 weeks.

"We are extremely disappointed with these unexpected results," the Geneva-based company said, adding that it would explore potential repositioning of the product candidate.

ObsEva licensed nolasiban, an oral oxytocin receptor antagonist, from Merck KGaA (MRK.XE) and retains worldwide, exclusive commercial rights.

 

Write to Colin Kellaher at colin.kellaher@wsj.com

 

(END) Dow Jones Newswires

November 07, 2019 06:53 ET (11:53 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.